Virax Biolabs Group LtdNASDAQ:VRAXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.7000
- TODAY'S CHANGE (%)0.0364 (5.4852%)
- Bid / Lots0.6300/ 2
- Ask / Lots0.7170/ 1
- Open / Previous Close0.7020 / 0.6636
- Day Range
- 52 Week Range
- Volume8,496
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | VRAX |
|---|---|---|
| 09:32 ET | 251 | 0.702 |
| 11:49 ET | 1000 | 0.695934 |
| 12:20 ET | 100 | 0.6602 |
| 02:45 ET | 100 | 0.7 |
| 02:47 ET | 100 | 0.7 |
| 03:05 ET | 862 | 0.7 |
Today
Apr 16, 2024
Virax Biolabs to Participate at ESCMID Global 2024, from 7:30AM ET on Tuesday Apr 16, 2024 by Dow Jones
7:30AM ET on Tuesday Apr 16, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Virax Biolabs Group Ltd | 1.6M | -0.5x | --- |
180 Life Sciences Corp | 1.6M | 0.0x | --- |
CTT Pharmaceutical Holdings Inc | 1.5M | -0.5x | --- |
Bluejay Diagnostics Inc | 1.5M | -0.1x | --- |
GRI Bio Inc | 1.4M | 0.0x | --- |
Innovation Pharmaceuticals Inc | 1.3M | -0.4x | --- |
Company Information
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing a T-Cell Test technologies with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against global viral threats. Its product portfolio includes ViraxClear and Virax Immune. ViraxClear offers a range of accurate diagnostic testing kits and machines. Virax Immune is a new Covid-19 test seeking detection of T-Cell immune responses to the SARS-Cov-2 virus. Its T-Cell testing is effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Monkeypox, Hepatitis B, Malaria, Herpes and Human Papillomavirus.
Contact Information
- Headquarters
- Biocity Glasgow, Bo'ness Road, NewhouseLONDON, United Kingdom ML1 5UH
- Phone
- 207-788-7414
- Fax
- ---
Executives
- Chairman of the Board, Chief Executive Officer
- James Foster
- Chief Financial Officer
- Jason Davis
- Chief Operating Officer, Director
- Cameron Shaw
- Chief Technical Officer
- Mark Ternouth
- Chief Scientific Officer
- Tomasz George
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.6M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 2.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.50 |
Book Value | $-0.86 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
